Committee Composition

Our next-generation viral immunotherapies pack a powerful trio of attributes – selective attack, potent destruction, and broad immune stimulation – to enable the potential to transform outcomes for patients.

Page Navigation

	Audit Committee	Compensation Committee	Nominating and Corporate Governance Committee
Non-Independent Directors
Scott Canute		Compensation Committee	Nominating and Corporate Governance Committee
Luke Evnin PhD	Audit Committee	Compensation Committee	Nominating and Corporate Governance Committee
Mary Kay Fenton	Audit Committee
Robert Kirkman, MD			Nominating and Corporate Governance Committee
Spencer Nam, MBA	Audit Committee
Cameron Wheeler, PhD		Compensation Committee	Nominating and Corporate Governance Committee